Results 191 to 200 of about 411,997 (358)

Increased cervical cancer incidence in the target age of screening—Variation by mode of detection

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Cervical cancer rates have risen in several high‐income countries despite advances in screening. Here, using data on cervical cancer diagnoses between 1996 and 2022 in Finland, the authors examined incidence trends according to detection mode—screening, between screenings, or outside screening programs—with attention to the role of human ...
Jenna Snellman   +4 more
wiley   +1 more source

Cost‐effectiveness of risk‐stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Effective cervical cancer prevention centers around screening and testing for human papillomavirus (HPV) infection. With birth cohorts of HPV‐vaccinated women now reaching screening‐eligible ages, however, the best means to maintaining cost‐effective cervical cancer screening is unclear.
Tiago M. de Carvalho   +2 more
wiley   +1 more source

Optimal cervical cancer screening strategies for unvaccinated and HPV-vaccinated cohorts in the United States: a comprehensive comparative modeling analysis. [PDF]

open access: yesLancet Reg Health Am
de Bondt DD   +11 more
europepmc   +1 more source

Morphological analysis of relationship between oral cytology and biopsy in diagnoses of leukoplakia or oral lichen planus

open access: green, 2016
Kenichi Matsuzaka   +13 more
openalex   +2 more sources

Giemsa-based cytological assessment of area, shape and nucleus:cytoplasm ratio of goblet cells of rabbit bulbar conjunctiva [PDF]

open access: yes, 2016
Carillo MP   +8 more
core   +1 more source

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia   +4 more
wiley   +1 more source

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

open access: yesThe Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy